News
-
-
-
REGULATED PRESS RELEASE
NFL Biosciences announces results from a new study conducted with the CEA providing further insight into the effects of NFL-101, its first-in-class treatment for tobacco addiction, and highlighting its prolonged activity
NFL Biosciences announces results from a new study with CEA on NFL-101, a treatment for tobacco addiction, highlighting prolonged activity & unique effect, showcased via PET imaging -
-
-
REGULATED PRESS RELEASE
NFL Biosciences presents its 2024 annual results and provides an update on its clinical program
NFL Biosciences presents 2024 annual results and clinical program update. NFL-101 phase 2 efficacy, innovative action with CEA, Phase 3 study plans, financing strategy, low cash burn until Q4 2025 -
-
REGULATED PRESS RELEASE
NFL Biosciences presents the immunological analysis results of its phase 2 CESTO II study confirming the efficacy of NFL-101, its first-in-class treatment for tobacco addiction
NFL Biosciences presents immunological analysis results of phase 2 CESTO II study confirming efficacy of NFL-101 for tobacco addiction. Association between anti-tobacco IgG increase and continuous abstinence strengthens evidence -
-
